62952-06-1

Basic information

• Product Name: DL-Lysine acetylsalicylate
• Synonyms: Lysine, 2-(acetyloxy)benzoate (1:1);Lysine, monosalicylate acetate (ester), D;Solpirin;Venopirin;(±)-Lysine·2-acetyloxybenzoate;Aspirin DL-lysin;DL-Lysine·2-acetyloxybenzoate;Lysin acetylsalicylate
• CAS NO: 62952-06-1
• Molecular Formula: C₆H₁₄N₂O₂*C₉H₈O₄
• Molecular Weight: 326.34
• EINECS: 263-769-3
• Product Categories: Aromatics;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 62952-06-1.mol
• Article Data: 2

Chemical Properties

• Melting Point: 154-156°C
• Boiling Point: 464.39°C (rough estimate)
• Flash Point: 131.2 °C
• Appearance: Crystalline solid
• Density: 1.1829 (rough estimate)
• Vapor Pressure: 0.000124mmHg at 25°C
• Refractive Index: 1.6280 (estimate)
• Storage Temp.: -20°C Freezer
• Solubility: Methanol (Slightly), Water (Slightly)
• CAS DataBase Reference: DL-Lysine acetylsalicylate(CAS DataBase Reference)
• NIST Chemistry Reference: DL-Lysine acetylsalicylate(62952-06-1)
• EPA Substance Registry System: DL-Lysine acetylsalicylate(62952-06-1)

Safety Data

• Hazardous Substances Data: 62952-06-1(Hazardous Substances Data)

Usage

Chemical Properties

Crystalline Solid

Uses

Different sources of media describe the Uses of 62952-06-1 differently. You can refer to the following data:
1. Non-steroidal anti-inflammatory drugs (NSAIDs) may inhibit cancer growth. Water soluble, injectable aspirin derivative. Analgesic; antipyretic; anti-inflammatory.
2. Non-steroidal anti-inflammatory drugs (NSAIDs) may inhibit cancer growth. Water soluble, injectable aspirin derivative.Analgesic; antipyretic; anti-inflammatory.

InChI:InChI=1/C9H8O4.C6H14N2O2/c1-6(10)13-8-5-3-2-4-7(8)9(11)12;7-4-2-1-3-5(8)6(9)10/h2-5H,1H3,(H,11,12);5H,1-4,7-8H2,(H,9,10)

Synthetic route

2,6-diaminocaproic acid (70-54-2, 923-27-3, 6899-06-5, 60103-30-2, 60132-27-6, 56-87-1) + aspirin (50-78-2) → lysine Acetylsalicylate (62952-06-1)

Conditions	Yield
In ethanol; water for 0.533333h; Time;	95%
In water; acetone at -15 - 15℃; for 1h; Concentration;	92.4%

Upstream product

• 70-54-2 2,6-diaminocaproic acid 
• 50-78-2 aspirin 

Relevant articles and documents

IMPROVED SYNTHESIS OF LYSINE ACETYLSALICYLATE · GLYCINE PARTICLES

The invention relates to a method for the production of acetylsalicylic acid lysinate, optionally lysine acetylsalicylate · glycine, comprising the following steps: a) providing a solution of acetylsalicylic acid in ethanol; b) providing an aqueous solution of lysine; c) combining the solutions of step a) and b) to form a mixture; d) optionally stirring the mixture; e) adding acetone to the mixture; f) incubating the mixture, to allow the formation of a acetylsalicylic acid lysinate product; g) isolating the acetylsalicylic acid lysinate product; wherein acetylsalicylic acid is used in excess compared to lysine and wherein no seed crystals are added to the mixture; and optionally the following further steps: h) providing a recrystallized glycine; wherein the glycine has been recrystallized with the following steps: h1) dissolving glycine in water; h2) adding acetone to the glycine solution; h3) stirring the mixture until a precipitate is obtained; i) combining the recrystallized glycine of step h) with the acetylsalicylic acid lysinate product of step g) to obtain lysine acetylsalicylate · glycine (LASAG) particles.